Advertisement

Topics

Novartis Reports Positive Results from Late-Stage Trial of Kisqali Combo Therapy in Advanced Breast Cancer

09:47 EST 8 Nov 2017 | Speciality Pharma Journal

Basel, November 8, 2017 – Novartis today announced positive topline results from the global MONALEESA-7 trial, the second Phase III trial of Kisqali® (ribociclib) in advanced or metastatic breast cancer. The MONALEESA-7 trial met its primary endpoint of progression-free survival (PFS) in premenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer. MONALEESA-7 …

Original Article: Novartis Reports Positive Results from Late-Stage Trial of Kisqali Combo Therapy in Advanced Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Novartis Reports Positive Results from Late-Stage Trial of Kisqali Combo Therapy in Advanced Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...